Immacule Lifesciences Private Limited – FDA 483, Jun 20, 2022
Immacule Lifesciences Private Ltd. India received an FDA Form 483 with eight observations, highlighting significant deficiencies in aseptic processing, quality control, and environmental monitoring. The firm failed to maintain adequate environmental controls during power outages, did not adhere to its stability testing program, and exhibited issues with quality control unit procedures and testing method suitability. Additionally, there were concerns regarding microbiological contamination prevention and continuous temperature monitoring for active pharmaceutical ingredients.
ID · b81f665f-d73e-486c-a38a-e8b2b3c54129
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.